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ABSTRACT 
Although a large body of evidence supports the notion that genes determine cardio-metabolic 
traits and outcomes, the non-genetic regulation of these events has recently gained increasing 
attention. Plastic chemical modifications of DNA-histone complexes defined epigenetic 
changes regulate gene expression by modifying chromatin accessibility to transcription 
factors. In the present thesis, we have investigated the emerging role of epigenetic 
modifications as fine-tuning regulators of gene expression in diabetic cardiomyopathy, as 
well as in obesity and diabetes-driven endothelial dysfunction.  
Study I: The objective was to investigate whether mitochondrial adaptor p66Shc contributes 
to obesity-related vascular dysfunction. Oxidative stress and vascular expression of chromatin 
modifying enzymes were investigated in visceral fat arteries (VFA) from obese and age-
matched healthy subjects. VFA from obese patients displayed enhanced mitochondrial 
reactive oxygen species (ROS) and endothelial dysfunction as well as a significant 
dysregulation of chromatin modifier enzymes methyltransferase SUV39H1, demethylase 
JMJD2C and acetyltransferase SRC-1 as compared to control VFA. These changes were 
associated with reduced methylation and acetylation of histone 3 lysine 9 (H3K9) on p66Shc 
promoter. Specifically, we demonstrated that obesity-induced downregulation of SUV39H1 
orchestrates JMJD2C/SRC-1 recruitment to p66Shc promoter, fostering adverse H3K9 
remodeling and p66Shc upregulation. 
Study II: We sought to investigate whether epigenetic regulation of pro-oxidant adaptor 
p66Shc contributes to persistent myocardial dysfunction despite intensive glycemic control 
(IGC). p66Shc expression was increased in the heart of diabetic mice, and IGC did not revert 
this phenomenon. Dysregulation of methyltransferase DNMT3b and deacetylase SIRT1 
linked to upregulation of miRNAs (miR-218 and miR-34a) drive persistent transcription of 
the adaptor p66Shc, thereby leading to mitochondrial oxidative stress, myocardial 
inflammation and left ventricular dysfunction. Our findings showed that adverse epigenetic 
signatures on p66Shc promoter contribute to left ventricular (LV) dysfunction in the setting of 
diabetes. 
Study III:  Here we demonstrate for the first time a protective role of activated protein-1 
(AP-1) transcription factor JunD against derangement of ROS homeostasis, inflammation and 
myocardial impairment in the setting of diabetes-induced hyperglycemia. JunD 
transcriptional activity was reduced in the heart of wild-type mice with streptozotocin-
induced diabetes and was associated with downregulation of free radical scavengers, 
increased expression of ROS-generating NADPH oxidase and marked increase in myocardial 
superoxide anion generation. These redox changes were paralleled by activation of NF-κB-
dependent inflammatory pathways and left ventricular dysfunction. Interestingly enough, 
such detrimental changes did not occur in diabetic mice with cardiac-specific overexpression 
of JunD (α-MHC-JunDtg) and LV function was not impaired, indicating the relevant role of 
JunD in counteracting hyperglycemia-induced redox changes and cardiac damage in diabetes. 
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Study IV: Enhancer of zeste homologue 2 (EZH2), a member of the family of SET1 
methyltransferase and a catalytic component in the polycomb repressive complex 2, is 
associated with transcriptional repression through histone H3K27me3 modification. 
Therefore, we hypothesize that its pharmacological modulation could have an impact on 
hyperglycemia-driven endothelial dysfunction. We demonstrated that pharmacological 
inhibition of EZH2 by GSK126 might prevent key hallmarks of diabetic vascular 
dysfunction, such as oxidative stress and inflammation. Experiments in human aortic 
endothelial cells showed that GSK126 protects against hyperglycemia-induced oxidative 
stress and inflammation via restoration of JunD, SOD1 and SOD2 expression and inhibition 
of Nox4 upregulation. Moreover, GSK126 was able to prevent activation of transcription 
factor NF-kB and subsequent upregulation of inflammatory adhesion molecules IL-6 and 
MCP-1. 
Altogether, our studies provide novel molecular insights on the regulation of redox and 
inflammatory pathways implicated in the impairment of obesity and diabetes-induced 
endothelial and cardiac function. Moreover, by targeting epigenetic changes responsible of 
derailed pro-oxidant and pro-inflammatory transcriptional programmes, we shed some light 
on putative pharmacological strategies to reduce the burden of cardiovascular disease in this 
setting.  
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1 INTRODUCTION 
 
1.1 GLOBAL BURDEN OF METABOLIC DISEASES 
The prevalence of obesity and type 2 diabetes (T2D) is alarmingly increasing worldwide at an 
unprecedented rate.1, 2 The main determinants behind this process are modifiable 
(environment, overnutrition, sedentary habits, smoking, etc.) and non-modifiable factors such 
as genetic susceptibility and aging.3 Environmental changes and physical inactivity are 
capable to alter gene expression and thereby cellular processes, and these derangements can 
be transmitted to offspring, hence, anticipating metabolic traits even in young normal weight 
individuals.4, 5 Accordingly, obesity and pre-diabetes are dramatically increasing in young 
adolescents and represent a severe public health problem.1, 6 The International Diabetes 
Federation currently estimates that worldwide almost 1.1 billion people will be overweight 
and 500 million people obese by the year 2040.7 Increase in body weight and visceral fat 
accumulation associate with several cardiovascular risk factors, such as insulin resistance, 
low-grade inflammation, arterial hypertension and dyslipidemia, which contribute to increase 
morbidity and mortality in these individuals.3, 8 Noteworthy, overweight and obesity are 
powerful predictors of T2D.9 The development of T2D from pre-diabetes occurs along a 
“continuum”, not necessarily linear with time, that includes different cellular mechanisms 
such as changes in glucose transport, tissue-specific alterations of insulin signaling, beta cell 
dysfunction as well as deregulation of important genes involved in oxidative stress and 
inflammation.10-12 High glucose and insulin levels in obese patients associate with increased 
cardiovascular risk, even without diabetes.13 Among the constellation of weight-related 
comorbidities, cardiovascular disease (CVD) carries the largest burden.11 Indeed, risks of 
coronary heart disease and ischemic stroke rise steadily with increasing BMI, a measure of 
weight relative to height. 12 Previous studies have shown that the expression of oxidant genes 
is also derailed in obese subjects.14, 15 However, the underlying mechanisms remain poorly 
understood.   
Currently, 425 million people have been diagnosed with diabetes worldwide and anticipate an 
increase up to 629 million by the year 2045.1 Furthermore, over the last decade, the 
prevalence of diabetes is increasing more in middle low-income countries than high-income 
countries. The most part of people living in these countries are unaware of the disease and 
remain undiagnosed for many years, leading to clear delays in the implementation of 
prevention and treatment strategies.1 Diabetes is a complex disease characterized by an array 
of different mechanisms ultimately resulting in elevated blood glucose levels.16 The disease 
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occurs when either the pancreatic beta cells are not able to produce enough insulin (a 
hormone that promotes the glucose absorption from the blood into adipose tissue, skeletal 
muscle and liver cells) or when the body fails to use the insulin effectively. This results in 
elevated blood glucose levels. Diabetes is associated with high morbidity and mortality, due 
to serious complications occurring primarily in the cardiovascular system (heart failure, 
coronary heart disease, peripheral artery disease, and stroke). Diabetes also affects the 
kidneys (diabetic nephropathy), the eye (retinopathy), the peripheral nervous system 
(neuropathy).17 Apart from them, diabetes also increases susceptibility to cognitive decline, 
cancer, infections and gastrointestinal disease.18, 19 Only 5% of people have type 1 diabetes 
(T1D).20 Patients who develop T2D are generally sedentary and obese. The progression from 
impaired glucose tolerance, a condition defined as pre-diabetes, to T2D may take many years 
to occur, leading to different intermediate disease phenotypes with continuous changes in 
glucose parameters and shifts in glucose tolerance category.3, 21 Hence, understanding the 
factors predisposing to T2D is a major challenge. The annual reported rate of T2D varies 
from 2-11 % in individuals with impaired fasting glucose (IGT) and 1-10 % in individuals 
with impaired fasting glucose (IFG), depending on the risk profile of different study 
populations.22-25 
1.2 ASSOCIATION OF DIABETES AND CARDIOVASCULAR DISEASE 
There is a strong biological link between T2D and cardiovascular disease (CVD).26 
Cardiovascular disease, including stroke, coronary heart disease, heart failure, are common 
causes of morbidity and mortality among patients with T2D.27 In these patients, metabolic 
alterations (insulin resistance, reduce insulin secretion or both) are responsible for endothelial 
dysfunction, inflammation and platelet reactivity. These conditions trigger and accelerate 
atherosclerotic vascular disease.28, 29 The deleterious effect of diabetes on cardiovascular 
system is highlighted by the fact that 75% of deaths in diabetic subjects are due to CVD.30 A 
seminal Finish study revealed that diabetes raises the 7-year risk of myocardial infarction and 
death in aged subjects.31 In addition, patients with diabetes also have an increased rate (three-
to-six-fold) of ischemic cerebrovascular complications.32, 33 Certainly, T2D was a potent 
predictor of stroke in subjects enrolled in a prospective Finnish study.34 In the Euro Heart 
Survey, one-year follow-up survival was significantly higher in pre-diabetic patients than in 
patients with T2D.35 However, in the long-term survival curves tend to overlap, hence 
strengthening the idea that all stages of impaired glucose regulation are linked with increased 
cardiovascular risk.36, 37 
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1.3 MULTIFACTORIAL INTERVENTION AND CARDIOVASCULAR RISK 
Advances in therapy have reduced morbidity and mortality in patients with diabetes. 
However, cardiovascular risk is far from being eliminated, and mechanism-based therapeutic 
strategies are in high demand.29 High glucose levels trigger endothelial inflammation, 
mitochondrial oxidative stress, and reduced availability of nitric oxide in patients with 
diabetes.28 This chain of events favors the development of macro- and microvascular 
disease.28 Although the link between obesity/diabetes and atherosclerosis is well established, 
a better comprehension of the underlying mechanisms is of utmost importance to identify 
novel molecular targets. 
1.4 REDOX CHANGES AND VASCULAR DYSFUNCTION 
In the last two decades, basic and translational research have unmasked a strong biological 
relation between high glucose, impaired insulin signaling and CVD in the setting of T2D.38-41 
However, despite these investigations provided important mechanistic insights, the 
detrimental effects of hyperglycemia and insulin resistance on the heart and vessels remain to 
be fully elucidated.42 Recent studies performed in endothelial cells isolated from patients with 
T2D have shown  activation of detrimental pathways favoring mitochondrial disruption and 
apoptosis.43 It was demonstrated that reactive oxygen species (ROS) are upstream regulators 
of complex molecular networks leading to endothelial dysfunction and, hence, vascular 
diabetic complications.29, 39, 44 In patients with diabetes, hyperglycemia leads to the generation 
of excessive mitochondrial ROS and subsequent activation of advanced glycation end 
products (AGEs), protein kinase C (PKC), nuclear factor-kB (NF-κB), polyol and 
hexosamine flux (Figure 1).45 This hyperglycemic environment induces a chronic elevation 
of diacylglycerol levels in endothelial cells with subsequent membrane translocation of 
conventional (α, β1, β2) and non-conventional (δ) PKC isoforms. Specifically, PKCβ2 isoform 
is highly activated in the diabetic endothelium and correlates with oxidative stress, impaired 
insulin signaling and, most importantly, endothelial dysfunction.46 One mechanism by which 
PKCβ2 elicits its deleterious effect is through the mitochondrial adaptor p66Shc.28, 47 Indeed, 
glucose-induced activation of PKCβ2 isoform phosphorylates the adaptor p66Shc at serine 36, 
favoring its localization to the mitochondria, oxidation of cytochrome c and subsequent ROS 
generation48, 49. Adaptor p66Shc functions as a redox enzyme implicated not only in 
mitochondrial ROS generation but also in the translation of oxidative signals into apoptosis.50, 
51 In this regard, diabetic p66Shc-/- mice are protected against hyperglycemia-induced 
endothelial dysfunction and oxidative stress.52 Besides, the relevance of p66Shc in the clinical 
setting of diabetes is further supported by the notion that p66Shc gene expression is increased 
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in peripheral blood mononuclear cells obtained from patients with T2D and correlates with 
plasma isoprostane levels, a reliable in vivo marker of oxidative stress.53 In addition, we have 
demonstrated that hyperglycemia-induced p66Shc upregulation is not reverted by intensive 
glycemic control in diabetic mice and contributes to persistent oxidative damage and vascular 
dysfunction via a complex vicious cycle involving ROS, epigenetic changes and PKC 
activation.54 Interestingly enough, in vivo gene silencing of p66Shc, performed at the time of 
normoglycemia restoration with insulin, was able to blunt persistent endothelial dysfunction, 
showing that p66Shc is an important source of free radicals involved in the “metabolic 
memory” phenomenon.54, 55 Altogether these findings indicate that knocking down p66Shc 
gene may be a promising option to rescue vascular dysfunction in diabetes. Another major 
source of ROS by PKC is via activation of NADPH oxidase subunit p47(phox). Indeed, 
treatment with a PKC inhibitor blunts NADPH-dependent ROS generation.39, 56, 57 A previous 
study from our group showed that PKCβ2 is also a regulator of NF-kB signaling in 
hyperglycemic conditions. PKCβ2 activation reduces protein levels of the inhibitory subunit 
NF-κB (Ik-Bα) thus enabling NF-kB-driven transcription of VCAM-1.47 Selective PKCβ2 
inhibition abolished Ik-Bα degradation thereby preventing hyperglycemia-induced 
endothelial inflammation. Taken together, PKC could be regarded as a key upstream 
regulator of hyperglycemic damage as well as impaired insulin signaling.48 Although the 
complete understanding of hyperglycemia-driven oxidative and inflammatory regulatory 
pathways remains challenging, targeting specific molecular mechanisms may represent a 
promising strategy to reduce cardiovascular burden in patients with diabetes.  
 
 
 
 
 
 
Figure 1. Mechanisms of glucose-induced vascular damage. PKC protein kinase C, eNOS endothelial nitric 
oxide synthase, ET-1 endothelin 1, ROS reactive oxygen species, NO nitric oxide, MCP-1 monocyte 
chemoattractant protein-1, VCAM-1 vascular cell adhesion molecule-1, ICAM-1 intracellular cell adhesion 
molecule-1, AGEs advanced glycation end products (modified from Paneni et al., 2013). 
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1.5 HEART FAILURE IN DIABETES 
It is well established that patients with diabetes have a high risk of left ventricular 
dysfunction and heart failure (HF) as compared with non-diabetic subjects.58-60 
Epidemiological studies have shown that poor glycaemic control is associated with an 
increased risk of HF.61 Recent studies clearly indicate that hyperglycaemic environment 
contributes to myocardial damage. Overproduction of ROS in mitochondria alters myocyte 
functionality leading to myocardial dysfunction, inflammation and fibrosis.62, 63 Therefore, 
understanding the molecular mechanisms of cardiac redox signalling may have important 
implications to counteract maladaptive changes occurring in the diabetic heart.64 
1.6 PATHWAYS LINKING AGING AND METABOLISM  
Over the last few years, molecular investigations have unveiled common signaling networks 
linking the aging process with deterioration of cardiovascular homeostasis and metabolic 
disturbances. Aging is not only able to impair pathways leading to adverse metabolic profile, 
but also conditions, such as obesity, diabetes and insulin resistance, anticipate vascular and 
cardiac senescence.  It is emerging that a dynamic interplay between p66Shc, NF-kB and 
activator protein-1 (AP-1) transcription factor JunD may favor adverse vascular and cardiac 
phenotypes in this setting.  
Recent studies have demonstrated that the adaptor p66Shc is an important molecular effector 
that may explain how aging is connected with metabolic and cardiovascular disease. p66Shc-/- 
mice exposed to oxidative stimuli have shown reduced levels of free radicals50, 65, an 
observation explained by the well-known concept that p66Shc is a major source of ROS.66 In 
line with these data, we observed that aging-induced impairment of endothelium-dependent 
relaxation to acetylcholine was not present in p66Shc-/-,67 due to preservation of nitric oxide 
availability in mice lacking p66Shc gene.67 Further work has demonstrated that p66Shc 
activation is critically involved in different processes including adipogenesis, insulin 
resistance and diabetes-related cardiovascular complications.52, 68 More recently, we found 
that p66Shc levels are increased in genetically obese mice and participate in endothelial insulin 
resistance.69 Activation of p66Shc also predispose to the acquisition of the heart senescent 
phenotype and development of heart failure in diabetic mice 70. Gene expression of p66Shc is 
increased in mononuclear cells obtained from patients with T2D and coronary artery 
disease.53, 71 Based on this background, it is possible to conclude that p66Shc fosters ROS 
accumulation, with subsequent deregulation of pathways implicated in mitochondrial 
dysfunction, fat accumulation, insulin resistance and diabetes.  
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Activation of NF-kB mediates vascular and myocardial inflammation in metabolic and age-
related diseases. A recent study clearly demonstrated that endothelial suppression of NF-kB 
prolongs lifespan in mice and improves obesity-induced endothelial insulin resistance. 
Interestingly, transgenic mice with endothelium-specific overexpression of the inhibitory NF-
kB subunit were protected against insulin resistance in adipose tissue and skeletal muscle.72 
Impaired insulin signaling is indeed an important hallmark linking metabolic disease with 
premature aging.73    
An emerging player in adverse cardiovascular remodeling is JunD, a member of the activated 
protein 1 (AP-1) family of transcription factors that is a major gatekeeper against oxidative 
stress. AP-1 is a heterodimeric complex which is composed of several proteins belonging to 
the c-Fos, c-Jun, ATF and CREB families.74 AP-1 modulates gene expression in response to 
cellular environment (infections, stress, cytokines, growth factors) 74. JunD, which is the most 
recently known gene of the Jun family, regulates cell growth and survival and protects against 
oxidative stress by modulating genes involved in antioxidant defense and ROS production.75 
Accordingly, JunD-/- mice exhibit features of premature aging, shortened life span and 
increased incidence of aggressive cancers.76-78 Recent evidence demonstrated an 
accumulation of ROS in JunD-/- murine embryonic fibroblasts which was reduced by 
treatment with ascorbate.75 By contrast, overexpression of JunD abolished ROS production, 
blunted redox signaling and apoptosis.75, 78 Gene expression profiling of JunD-/- murine 
embryonic fibroblasts showed downregulation of several free radical scavenging enzymes 
associated with an increase in expression of ROS-producing NADPH oxidase.75 In this 
regard, we have recently reported that JunD is highly relevant for cardiovascular 
homeostasis.78 We observed that vascular JunD expression declines with aging, thus altering 
the balance between pro-oxidant (NADPH oxidase) and antioxidant enzymes (manganese- 
superoxide dismutase and aldehyde dehydrogenase-2), with subsequent accumulation of free 
radicals. Indeed, genetic deletion of JunD in young mice was associated with premature 
disturbances of redox signaling, mitochondrial disruption and endothelial dysfunction.78 
Moreover, young JunD-/- mice displayed premature features of vascular senescence, which 
were comparable with those observed in aged animals. We found that age-dependent 
downregulation of JunD was the result of epigenetic changes occurring on its promoter.78 
This finding is in agreement with the notion that epigenetics may significantly alter the 
expression of genes involved in senescence, metabolic disorders and cardiovascular 
damage.78 Interestingly enough, JunD expression was reduced in peripheral blood monocytes 
isolated from aged compared to young healthy subjects. Taken together, the results of this 
work imply that JunD can be considered as an attractive molecular target to prevent or delay 
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age-driven cardiovascular diseases. In agreement with our observations, genetic manipulation 
of JunD (disruption or overexpression) promotes pressure overload-induced apoptosis, 
hypertrophic growth and angiogenesis in the heart79 and blunts phenylephrine-mediated 
cardiomyocyte hypertrophy.80 Notably, JunD protein levels are decreased in patients with 
end-stage heart failure.81 Reduced JunD levels may also affect longevity by controlling 
pathways relevant to angiogenesis and insulin signaling. It has been reported that insulin-
IGF-1 signaling is constitutively stimulated in mice lacking JunD, leading to inactivation of 
FOXO1, a positive regulator of longevity.76 Similarly, JunD-/- mice display hyperinsulinemia, 
most probably resulting from enhanced pancreatic islet vascularization due to chronic 
oxidative stress.76 Interestingly, long-term treatment with an antioxidant rescued the 
metabolic disturbances observed in JunD-/- mice.76 These data clearly indicate that JunD can 
be regarded as a major effector in the interplay between aging, metabolism and 
cardiovascular disease. 
1.7 THE ROLE OF EPIGENETICS IN CARDIOMETABOLIC DISEASES 
Eukaryotic chromosome is composed of histone-DNA complexes forming the chromatin that 
are organized into subunits called nucleosomes. In nucleosomes, chromosomal DNA is 
packaged around histone proteins.15 Epigenetic changes refer to plastic and dynamic chemical 
changes of DNA/histone complexes that can modify gene regulation without changing the 
DNA sequence.82 Epigenetic alterations can be classified into three main types: 1) DNA 
methylation; 2) post-translational histone modifications; 3) non-coding RNA (ncRNA).83 
DNA methylation is the process by which methyl group is covalently added to the carbon 5 
position of cytosine and thereby represses gene transcription, either by preventing 
transcription factor binding to the promoter region or by fostering the recruitment of 
chromatin remodeling enzymes.84 DNA methylation is catalyzed by a family of DNA 
methyltransferases (DNMTs), which include DNMT1, DNMT3a, DNMT3b. DNMT1 
maintains methylation status during replication whereas DNMT3a/DNMT3b are involved in 
de novo methylation.85  
DNA-related changes together with posttranslational modifications of histones such as 
acetylation, ubiquitination and phosphorylation may arrange in different patterns to regulate 
chromatin structure.86 In contrast to DNA methylation, impact of histone modifications on 
gene expression may differ depending on the particular chemical modification.87 For instance, 
lysine mono-methylation of histones generally activate gene transcription, but di- or 
trimethylation can either activate gene (e.g. H3K4me3) or repress gene transcription (e.g. 
H3K9me3).88 Non-coding RNAs do not affect chromatin structure directly but a play a 
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pivotal role in post-transcriptional regulations of genes.89 Of interest, non-coding RNAs 
strictly cooperate with both acetyl- or methyl writing and erasing enzymes to edit chromatin 
conformation and gene expression.90 It has been shown that microRNAs regulate the 
expression of both chromatin modifying enzymes as well as DNA methyl transferases  (i.e. 
DNMT3a and DNMT3b). On the other side, chromatin modifications may affect the 
transcription of non-coding RNAs.91 Thus, the distinct epigenetic processes are not 
independent, instead they can interact and influence each other. This complex regulation of 
gene transcription is also tissue and cell-specific.92  
Although great advancements in the field of epigenetic and cancer, the environmental 
regulation of gene expression in the setting of cardiometabolic diseases including diabetes 
remains poorly understood.93 Despite an established body of evidence supports the notion 
that genes influence the cardiometabolic features and outcomes, the epigenetic modifications 
occurring in this setting are gaining more attention.82 Given that epigenetic regulation is 
reversible in nature, novel avenues for therapeutic intervention in cardiometabolic diseases, 
including diabetes, are warranted.94 Although epigenetic drugs are well-known for their 
antineoplastic properties, they are currently investigated for non-oncological applications.94 
Among new emerging epigenetic drug target candidates, EZH2 (catalytic component 
Enhancer of zeste homolog 2) is a catalytic component of PRC2 complex, which methylates 
lysine 27 of histone H3. Trimethylation of lysine 27 of histone 3 (H3K27me3) is a repressive 
histone mark associated with suppression of gene expression.95 EZH2 regulation effects are 
involved in different physiological and pathological processes, including cancer.96-99 Several 
studies have reported EZH2 plays important role in ROS generation, cardiac hypertrophy and 
inflammation.100-102 Indeed, increased EZH2 expression blunts SOD-2 expression leading to 
increase ROS generation that contributes to progression of pulmonary artery hypertension.100 
A recent study demonstrated that targeting EZH2 in erythroid cells exposed to ferric 
nitrilotriacetate and cobalt-60 radiation protects against oxidative stress.103 Moreover, it has 
been shown that high glucose induces oxidative stress via increased expression of EZH2 in 
human mesenchymal stem cells.104 Similar to these findings, elevated levels of EZH2 
expression and activity in retinal tissues from diabetic animals and endothelial cells exposed 
to high glucose are linked to dysregulation of miR-200b and the development of diabetic 
retinopathy.105 Furthermore, several lines of evidence have implicated EZH2 upregulation in 
the development and progression of atherosclerosis. For instance, recent studies have shown 
increased H3K27me3 in endothelial cells isolated from early and advanced human 
atherosclerotic plaques.106 In addition, specific inhibition of EZH2 by a small molecule 
inhibitor protects against neuro-inflammation in microglial cells.102 Indeed, EZH2-dependent 
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conformational changes promote accumulation of free radicals and inflammation.100, 107 
Lastly, EZH2 is required for NF-κB signaling in cancer.108 Currently, strong efforts are made 
to selectively target EZH2. In this respect, GSK126 is a small-molecule inhibitor of EZH2 
that is more than 1000-fold selective for EZH2 over other methyltransferases and 150-fold as 
compared to EZH1.109 Thus, studies evaluating the effects of GSK126 deserve further 
investigation. 
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2 AIMS OF THE THESIS 
We hypothesize that obesity/diabetes-induced epigenetic changes may regulate ROS-driven 
vascular and cardiac dysfunction by altering the transcription of key genes implicated in 
redox balance and inflammatory-related pathways. Therefore, the overall aim of the present 
thesis was to investigate the molecular and cellular mechanisms underpinning 
obesity/diabetes-mediated vascular and cardiac dysfunction.  
Specific Aims 
v To study the role of epigenetic regulation of p66Shc in obesity-induced vascular 
dysfunction (Study I). 
v To investigate whether epigenetic regulation of p66Shc is responsible for persistent 
myocardial oxidative stress and inflammation despite intensive glycemic control (Study 
II). 
v To assess the protective effect of AP-1 transcription factor JunD in the diabetic heart 
(Study III). 
v To determine the role of histone methyltransferase EZH2 in high glucose-induced 
oxidative stress and inflammation (Study IV). 
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3 STUDY DESIGN AND METHODS  
 
The studies included in this thesis are based on the use of different in vitro and in vivo 
methods to address our specific research questions. A detailed description of the methods 
employed is reported in individual papers. 
3.1 PARTICIPANTS (STUDIES I AND III) 
In Study I, the clinical study population consisted on the inclusion of 21 subjects with severe 
abdominal obesity and 20 non-obese age-matched control subjects (Table 1). Obese subjects 
were recruited among 220 consecutive patients referred to the Department of Endocrinology 
(University of Pisa, Italy) from January 2010 to January 2014 for screening in view of 
laparoscopic bariatric surgery. The exclusion criteria were as follows: (a) history or clinical 
evidence of hypertension (blood pressure >140/90 mmHg), (b) smoking history, (c) ethanol 
consumption (more than 60 g or one-half liter of wine/day), (d) hypercholesterolemia, (e) 
diabetes mellitus, (e) overt cardiovascular disease, and (f) renal dysfunction or menopause. In 
addition, patients taking cardiovascular or metabolic drugs were also excluded. Control 
subjects were recruited among patients hospitalized in the Surgery Unit (University of Pisa, 
Italy) to undergo laparoscopic surgery for cholecystectomy. Ethical approval for the study 
was obtained from the Local Ethical Committee and all participants provided written 
informed consent for their participation.  
In study III, left ventricle specimens were obtained from cardiac biopsies performed in 5 
patients with diabetes and heart failure (New York Heart Association [NYHA] class III) and 
6 control subjects (Table 2) from the Advanced Study of Aortic Pathology (ASAP) biobank 
undergoing selective open-heart surgery for ascending aortic aneurysm at Karolinska 
University Hospital, Stockholm. The biopsies were immediately snap-frozen in liquid 
nitrogen and stored at -80°C. 
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Table 1. Demographics and laboratory parameters in the study I population 
 
  Controls (n = 20) Obese (n = 21) P-value 
Demographics 
Age (years)  49.5 (4.6) 48.4 (7.0) 0.551 
Gender (F:M)  11:9 13:8 0.690 
Body mass index 
(kg/m2)  
24.0 (1.9) 42.2 (5.0) <0.001 
Waist circumference 
(cm)  
92.9 (5.7) 135.3 (13.3) <0.001 
Systolic BP (mmHg)  125.5 (7.2) 129.9 (10.0) 0.116 
Diastolic BP (mmHg)  80.0 (76.5–82.0) 84.0 (80.0–87.0) 0.048 
Heart rate (bpm)  71.2 (6.2) 78.9 (7.1) 0.001 
Laboratory parameters 
Triglycerides (mg/dL)  119.5 (20.9) 141.4 (38.6) 0.031 
HDL cholesterol 
(mg/dL)  
50.5 (44.5–63.0) 42.0 (37.5–50.0) 0.001 
LDL cholesterol 
(mg/dL)  
124.6 (20.3) 138.7 (17.6) 0.022 
Total cholesterol 
(mg/dL)  
202.4 (18.0) 210.7 (18.7) 0.158 
FPG (mg/dL)  84.3 (7.7) 103.1 (7.9) <0.001 
Hb1Ac (%)  5.2 (0.2) 5.9 (0.1) <0.001 
Fasting insulin (µU/mL)  7.0 (0.5) 13.4 (1.3) <0.001 
HOMA-IR  1.5 (0.2) 3.7 (0.5) <0.001 
Creatinine (mg/dL)  0.9 (0.2) 0.8 (0.2) 0.115 
 
Values are expressed as mean (SD) or median (interquartile range). P-value refers to Student's t-test and χ2-tests. 
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; Hb1Ac, glycated 
haemoglobin; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin 
resistance; HR, heart rate; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; TG, 
triglycerides. 
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Table 2. Demographics and laboratory parameters in the study III population. 
 
 
Data are mean ± standard deviation unless otherwise indicated. BMI, body mass index; ACE, angiotensin 
converting enzyme inhibitors; ARB, angiotensin receptor blockers; MRA, mineralocorticoid receptor 
antagonists; LVEF, left ventricle ejection fraction; LVEDD left ventricle end diastolic diameter. 
  
Characteristics Patients with DM (n=5) 
Control subjects 
(n=6) p-value 
Age 64 ± 4.38 60 ± 11.10 0.51 
Gender (M/F) 4/1 6/0  
Weight (Kg) 86.42±12.18 87.33 ± 9.62 0.90 
BMI 29.76 ± 4.14 27.96 ± 2.73 0.45 
Blood pressure 
      Systolic (mmHg) 
 
110 (82;87) 
 
135 ± 21.7 
 
0.08 
      Diastolic (mmHg) 65 ± 12.98 84.6 ± 17.77 0.09 
Laboratory     
Creatinine (umol/L) 116 ± 43.23 85.16 ± 29.43 0.23 
Glucose (mmol/L) 10.05 ± 3.15 6 ± 0 <0.05 
Medications n (%) n (%)  
   ACE-Inhibitors 4 (80) 2 (33)  
   ARBs 2 (40) 2 (33)  
   β-blockers 5 (100) 5 (83)  
   MRAs 4 (80) --  
   Loop diuretics 5 (100) 1 (17)  
   Anticoagulants 3 (33) 1 (17)  
   Statins 5 (100) 5 (83)  
   Hypoglycemic agents 5 (100) --  
ECHO parameters    
LVEF (%) 20.8 ± 8.65 60.83 ± 4.48 <0.001 
LVEDD (mm) 67.2 ± 5.87 49.5 ± 3.77 <0.001 
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3.2 INDUCTION OF DIABETES (STUDIES II AND III) 
Diabetes was induced in 4-months old C57BL/6 wild type (WT) and α-MHC-JunDtg male 
mice by a single high dose of streptozotocin (STZ, 180 mg/KG, intraperitoneal), dissolved in 
sterile citrate buffer (pH 4.5) and injected within 15 minutes (min). Both control groups 
received citrate buffer alone. STZ-treated animals with 3 random blood glucose levels >13.9 
mmol/l defined as diabetic. Animals were housed under standard laboratory conditions with 
free access to water and laboratory chow diet. Animal experiments were followed in 
accordance with the guidelines approved by Institutional Animal Care Committee of 
Karolinska Institutet. All animals were euthanized after 4 weeks of follow-up.  
3.3 IN VIVO EDITING OF CHROMATIN MODIFIERS (STUDY I) 
For overexpression of SUV39H1, obese (LepOb/Ob) mice were either injected 40 µg of 
predesigned mouse SUV39H1 cDNA clone (MC200652) or cloning vector (PCMV6-
Kan/Neo, PCMV6KN) together with the cationic transfection reagent in vivo-jetPEI, 
according to instructions provided by manufacturer. For in vivo knockdown of JMJD2C and 
SRC-1, predesigned siRNAs were injected, as previously reported 110. Based on time-
dependent studies, SUV39H1 cDNA clone as well as JMJD2C and SRC-1 siRNAs were 
injected intravenously for four weeks after every five days. A scrambled-siRNA was used as 
a negative control.  
3.4 CONVENTIONAL ECHOCARDIOGRAPHIC MEASUREMENTS (STUDIES II 
AND III) 
Echocardiographic parameters were assessed before and four weeks after the diabetes 
induction. Mice were anesthetized with 2-5% of isoflurane mixed with oxygen. 
Echocardiography was performed to evaluate left ventricular functions by using high 
resolution Micro-Ultrasound System (Vevo 2100, Visualsonics) equipped with a 22-55 MHz 
(MS550D) linear array transducer. A rectal temperature probe was inserted to monitor and 
maintain mice body temperature at ~37°C using heating pad and heating lamp. The chest was 
shaved and pre-warmed ultrasonic gel was applied to the shaved site. M-mode and B-mode 
images were obtained at the mid-papillary level in the parasternal short-axis and long-axis 
views.  
3.5 SPECKLE-TRACKING BASED STRAIN MEASURES OF MYOCARDIAL 
DEFORMATION (STUDIES II AND III) 
It has been found that parasternal long-axis views are the most reproducible myocardial views 
for longitudinal strain analyses in mice. Parasternal short-axis views at the mid-papillary level 
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were acquired for circumferential and radial strain analyses, and all images were acquired at a 
frame rate >200 frames/second and at an average depth of 11 mm. Strain analyses were 
conducted by a single investigator on all groups of mice by using a speckle-tracking 
algorithm (VevoStrain, VisualSonics). 
3.6 ORGAN CHAMBER EXPERIMENTS (STUDY I) 
Mice were sacrificed by intraperitoneal injection of sodium pentobarbital (50 mg/Kg). The 
aorta was completely excised from the heart to the iliac bifurcation and put it immediately in 
cold modified Krebs-Ringer bicarbonate solution (pH 7.4, 37°C, 95% O2; 5% CO2) 
composed of the following constituents (in mmol/L): NaCl (118.6), KCl (4.7), CaCl2 (2.5), 
KH2PO4 (1.2), MgSO4 (1.2), NaHCO3 (25.1), glucose (11.1), and calcium EDTA (0.026). 
The aorta was then cleaned of fat and connective tissues and used immediately in isometric 
tension studies. Endothelium-dependent and endothelium-independent relaxations were 
determined in a pressurized myograph by measuring responses to cumulative concentrations 
of acetylcholine (Ach, 1 nmol/l to 100 µmol/l) and sodium nitroprusside (0.01 to 100 µmol/l), 
respectively. Vessels were pre-contracted with norepinephrine (NE, 1 µmol/l). 
3.7 ASSESSMENT OF SUPEROXIDE ANION GENERATION BY ESR 
SPECTROSCOPY (STUDIES I, III AND IV) 
Superoxide anion generation (O2-) was assessed in endothelial cells and mouse heart tissues 
by electron spin resonance (ESR) spectroscopy using the spin trap 1-hydroxy-3-
methoxycarbonyl-2,2,5,5-tetramethyl-pyrrolidine (CMH). O2- production was determined by 
the oxidation of 1-hydroxy-3-carboxy-pyrrolidine (CP-H) to paramagnetic 3-carboxy-proxyl 
(CP). Signals were quantified by measuring the total amplitude after correction of baseline 
and subtraction of background. 
3.8 MEASUREMENTS OF 3-NITROTYROSINE LEVELS (STUDY II) 
Levels of oxidative stress marker 3-nitrotyrosine (3-NT) in heart homogenates and cell 
lysates were measured using OxySelectTM Nitrotyrosine ELISA kit ((ab116691; Abcam) 
following the manufacturer`s instructions. Briefly, 50 µL of nitrated BSA standard or samples 
were added into nitrated BSA pre-absorbed enzyme-linked immunosorbent assay (EISA) 
plate and incubated for 2 hours. To each well, an anti-nitrotyrosine antibody was added and 
incubated for 1 hour followed by addition of HRP-conjugated secondary antibody. 
Development solution was added to each well following addition of stop solution. 
Absorbance was immediately read at 450 nm using spectrophotometer. Nitrotyrosine in 
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samples was determined by comparing with a standard curve prepared from predetermined 
nitrated BSA standards.  
3.9 NF-KB BINDING ACTIVITY (STUDIES II-IV) 
NF-κB p65 binding reaction was performed with 20 µg of nuclear lysate or 40 µg of whole 
cell lysate in a 96-well plate immobilized with consensus sequences for NF-κB 
(GGGACTTTCC) for 1 hour at RT. Then, washing (with washing buffer) and incubation 
(with anti- NF-κB p65 antibody for 1 hour at RT and, thereafter, with horseradish peroxidase-
conjugated secondary antibody) steps were performed. Finally, the degree of NF-κB p65 
DNA binding was assessed by spectrophotometry at 450 nm. 
3.10 ISOLATION OF MITOCHONDRIAL AND CYTOSOLIC FRACTION (STUDY 
II) 
Heart tissues were suspended in the mitochondrial buffer (10 mM KCl, 1.5 mM MgCl2, 1 
mM EDTA, 10 µg/mL leupeptin, 10 µg/mL aprotinin, and 0.25 M sucrose, pH 7.2). The 
tissues were gently homogenized with 30 strokes in a Dounce homogenizer. The homogenate 
was centrifuged at 750 xg for 10 min at 4°C to pellet nuclei and unbroken cells and the 
supernatant was collected and centrifuged at 10,000 xg for 15 min. The resulting 
mitochondrial-enrich pellet was collected by resuspending it in lysis buffer (named 
mitochondrial fraction) whereas the supernatant was referred as the cytosolic fraction.  
3.11 MITOCHONDRIAL SWELLING ASSAY (STUDY II) 
40 µg of freshly isolated mitochondria from mouse hearts in swelling buffer (containing 250 
mmol/L sucrose, 10 mmol/L MOPS, 5 µmol/L EGTA, 2 mmol/L MgCl2, 5 mmol/L 
KH2PO4, 5 mmol/L pyruvate, and 5 mmol/L malate) were incubated with 150 µmol/L of 
calcium chloride in a final volume of 200 µL in a 96-well plate for 20 min. Mitochondrial 
swelling was assessed by reading absorbance every 30 seconds at 520 nm.  
3.12 CHROMATIN IMMUNOPRECIPITATION ASSAY (STUDIES I- IV) 
For chromatin immunoprecipitation (ChIP), mouse heart tissues were diced and fixed in 
formaldehyde solution (1%). The homogenate was cross-linked for 10 min at room 
temperature (RT), and excessive formaldehyde was quenched by using 125 mM of glycine. 
After quenching, the homogenate was resuspended in SDS-based lysis buffer and sonicated 
to obtain chromatin fragments of 200 to 500 bp using a water bath sonicator. 
Immunopurification of soluble chromatin was performed using antibodies against JunD, 
H3K4me1, H3K4me3, H3K9me2, H3K9me3 and H3K27me3. The non-specific mouse IgG 
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antibody was used as negative control. The antibody-bound chromatin fraction was pulled 
down using dynabeads coated with protein A. Washing steps, revere cross-linking and 
purification of DNA conjugates were performed according to previously described 
protocol.101 ChIP-enriched DNA sequences were detected by using real-time PCR system. 
3.13 METHYLATED DNA ENRICHMENT (STUDY III) 
Isolated genomic DNA from mouse heart was fragmented to 150-300 bp using a Diagenode 
sonicator. Methyl-CpG-binding domin (MBD) protein was coupled with dynabeads. 
Fragmented genomic DNA was incubated with coupled MBD-beads on rotating mixer for 1 
hour at RT. Methylated DNA was eluted by 2M of NaCl buffer and precipitated with ethanol. 
The obtained sequences were quantified by real-time PCR.    
3.14 STATISTICAL METHODS 
Results were confirmed to follow a normal distribution with the Kolmogorov-Smirnov test of 
normality. All normally distributed variables are presented as mean (standard deviation), 
unless otherwise stated. Data that failed the normality assumption are shown as median 
(interquartile range). Comparisons of continuous variables were performed using unpaired 
two-sample t-test and Mann–Whitney U test, as appropriate. Categorical variables were 
compared using the v2 test.  Data that passed the normality assumption were analyzed using 
unpaired 2-sample t, whereas multiple comparisons were performed by 1-way analysis of 
variance (ANOVA) followed by Bonferroni correction. A multiple t-test using the Benjamin–
Hochberg false discovery rate procedure was employed for the analysis of gene expression 
data [real-time polymerase chain reaction (PCR) array]. Spearman ranked correlation test was 
used for correlation analysis. Probability values <0.05 were considered statistically 
significant. All statistical analyses were performed with GraphPad Prism Software (version 5, 
6.03, 7.03). 
 
4 RESULTS AND DISCUSSION  
 
4.1. Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-drives 
         p66Shc transcription and vascular oxidative stress in obesity (STUDY I) 
Current understanding of molecular pathways and biological processes unveiling vascular 
phenotype in patients with obesity is limited. Gene environment interaction as a putative 
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mechanism in vascular complications of obesity remains uncertain 111-113. A strong body of 
evidence supports the notion that endothelial dysfunction contributes to the development of 
obesity-related CVD 114. Accumulation of ROS generation is a key event preceding the 
development of endothelial dysfunction and vascular disease 114, 115. In this regard, 
mitochondrial adaptor p66Shc protein, which is part of a mitochondrial complex, regulates 
endogenous production of free radicals and apoptosis 66.  
Eukaryotic chromosome is composed of histone-DNA complexes forming the chromatin 
that are organized into subunits called nucleosomes. In nucleosomes, chromosomal DNA is 
packaged around histone proteins 15. A key mechanism that regulates chromatin 
organization is the covalent modification such as acetylation and methylation of specific 
amino residues on histone tails 116. These histone modifications may cluster in different 
orientations to regulate chromatin accessibility 117. For instance, acetylation of histone 3 at 
lysine 9 (H3K9ac) is associated to open chromatin and active gene transcription whereas 
methylation of histone 3 at lysine 9 (H3K9me) is associated to heterochromatin, 
characterized by tightly packed form of DNA and inactive gene transcription 118. Based on 
this background, we investigated whether chromatin modifications may regulate vascular 
ROS by modulating the transcription of the mammalian adaptor p66Shc, a key redox gene 
implicated in mitochondrial generation of free radicals and translation of oxidative signals 
into apoptosis 50, 51.   
First, we investigated the link between endothelial dysfunction, oxidative stress, and p66Shc 
gene expression in visceral fat arteries (VFAs) isolated from obese and control individuals.  
Obese subjects showed an impairment of acetylcholine-induced vasorelaxation as compare to 
control subjects (Figure 1a) Consistently, generation of mitochondrial superoxide anion (O2-) 
was higher in VFA from obese as compared to controls (Figure 1b). However, pretreatment 
with antioxidant prevented impaired relaxation to acetylcholine, suggesting that oxidative 
stress contribute to the impairment of endothelial function in this setting (Figure 1a). p66Shc 
gene expression was significantly increased in obese VFA as compared to control and was 
significantly correlated with endothelial impairment and mitochondrial oxidative stress in 
obese VFA (Figure 1d-e).  
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Figure 1. (a) Endothelium-dependent relaxation to Ach in small visceral fat arteries (VFA) isolated from obese 
subjects and age-matched healthy controls, in the presence or in the absence of antioxidant ascorbic acid; (b) 
ESR spectroscopy analysis of O2- generation in isolated mitochondria from VFA of obese patients and controls. 
(c) Gene expression of the mitochondrial adaptor p66Shc in isolated vessels from the two groups. (d-e) Spearman 
correlations of p66Shc gene expression with Ach maximal relaxations and mitochondrial O2-, respectively. (a) 
Repeated-measures analysis of variance (ANOVA) followed by Bonferroni’s post-test; (b-c) Student’s t-test; (d-
e) Spearman correlations, r= correlation coefficient. Data are expressed as means ± SEM, n= 20-21 per group. 
Ach, acetylcholine; O2-, superoxide anion. 
In order to investigate epigenetic regulation of p66Shc gene in obesity, we performed a real 
time PCR array for chromatin modifying enzymes in VFA isolated from obese and normal 
weight subjects. We observed 27 out 84 genes were deregulated in obese as compared to 
control VFA. Among these 84 genes, 21 were upregulated and 6 were downregulated in VFA 
from obese patients (see Figure 2; Paper I). Since previous studies have been shown that 
epigenetic regulations of p66Shc occur on histone 3 (H3), we performed chromatin 
immunopreciption (ChIP) to unveil H3 modifying enzymes interacting with p66Shc promoter. 
We found that only methyltransferase SUV39H1, demethylase JMJD2C and acetyltransferase 
SRC-1 were involved in epigenetic remodeling of H3K9 on p66Shc promoter (Figure 2A). 
Interestingly, acetylation of H3K9 on p66Shc promoter (H3K9ac) was increased, whereas di-
methylation (H3K9me2) and tri-methylation (H3K9me3) of H3K9 on p66Shc promoter were 
reduced in obese as compared to control VFA (Figure 2B). These findings suggest that 
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SUV39H1, JMJD2C and SRC-1 may contribute to p66Shc transcription, oxidative stress and 
vascular dysfunction in obese patients.  
 
Figure 2. Adverse epigenetic remodelling of H3K9 on human p66Shc promoter. (A) Real-time polymerase 
chain reaction array showing deregulated chromatin modifying enzymes in obese vs. control visceral fat artery. 
(A) change of at least two-fold (>2 or < −2) with P < 0.05 was considered significant; (B) Schematic showing 
ChIP-based selection of chromatin-modifying enzymes-binding p66Shc promoter; (C) Interaction of chromatin-
modifying enzymes SUV39H1, JMJD2C, and SRC-1 with human p66Shc promoter assessed by ChIP assays; (D) 
Methylation and acetylation of H3K9 on p66Shc promoter. Chromatin was immunoprecipitated with specific 
antibodies against H3K9m2, H3K9m3, and H3K9ac, and real-time polymerase chain reaction for 
p66Shc promoter was performed. Data are expressed as means ± standard deviation, n = 10 per group. H3K9, 
histone 3 lysine 9; AU, arbitrary units. 
Similar to the human findings, p66Shc gene expression was significantly increased in aorta of 
obese mice (LepOb/Ob). Endothelial function was impaired in obese mice as compared to WT 
controls, whereas p66Shc knockout obese mice were protective against endothelial 
dysfunction. Mitochondrial O2- levels were significantly increased in vasculature of LepOb/Ob  
but not in LepOb/Obp66-/- as assessed by ESR spectroscopy. We confirmed that H3K9 
modifying enzymes SUV39H1, Jmjd2C and SRC-1 were deregulated in the aorta isolated 
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from LepOb/Ob as compared to WT controls. Furthermore, H3K9ac was increased on p66Shc 
promoter whereas H3K9me2 and H3K9me3 were reduced in LepOb/Ob as compared to WT 
controls (see Figure 3; Paper I). 
To understand the contribution of H3K9 modifying enzymes SUV39H1, Jmjd2C and SRC-1 
to vascular oxidative stress, we selectively reprogrammed their expressions in endothelial 
cells isolated from LepOb/Ob  mice. Interestingly enough, we found that either overexpression 
of SUV39H1 or silencing of Jmjd2C and SRC-1 blunted p66Shc upregulation and vascular 
oxidative stress. These results were also confirmed in the in vivo setting. Our results 
demonstrated that SUV39H1, JMJD2C and SRC-1 were critically involved in p66Shc gene 
regulation. In order to understand how these enzymes functionally interact, we performed 
ChIP experiments to unveil functional molecular interactions among SUV39H1, JMJD2C 
and SRC-1. We found that binding of SRC-1 to p66Shc promoter was significantly reduced in 
the vasculature of LepOb/Ob mice treated either with SUV39H1 overexpressing vector or 
JMJD2C siRNA. In contrast, knockdown of SRC-1 did not affect the binding of SUV39H1 
and JMJD2C to p66Shc promoter. Of interest, only SUV39H1 overexpression blunted p66Shc 
transcription by recruitment of both JMJD2C and SRC-1 to p66Shc promoter (see Figure 4; 
Paper I). 
Previous studies have shown that H3K9 modifications are associated with impaired insulin 
signalling, deregulation of metabolic and inflammatory genes as well as changes in appetite 
119-123. More importantly, H3K9 and related histone marks have been found to contribute to 
intergenerational metabolic reprogramming with a profound impact on phenotype variation 
and evolution 124. However, modifications of H3K9 in obesity-induced oxidative stress and 
vascular phenotypes remain unmasked. This study showed for the first time that both human 
and experimental obesity are strongly associated with specific remodelling of H3K9, 
characterized by increased AcH3K9 and reduced H3K9me2 as well as H3K9me3. Strikingly, 
these epigenetic changes resulted due to deregulation of three chromatin modifying enzymes 
such as the methyltransferase SUV39H1, demethylase JMJD2C and acetyltransferase SRC-1 
interacting to the promoter of p66Shc gene. Among these three chromatin-modifying enzymes, 
we observed that SUV39H1 was downregulated whereas JMJD2C and SRC-1 were 
upregulated. This obesity-induced expression pattern led to increased H3K9 acetylation by 
SRC-1 and decreased methylation by SUV39H1 and JMJD2C, thus fostering the shift from 
heterochromatin to active euchromatin. Interestingly enough, either overexpression of 
SUV39H1 or gene silencing of JMJD2C and SCR-1 were able to edit the H3K9 landscape, 
thus blunting transcription of the adaptor p66Sh in endothelial cells both in vitro and in vivo 
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settings of obesity. Furthermore, we also found that SUV39H1 fosters JMJD2C/SRC-1 
recruitment to p66Shc promoter, however JMJD2C and SRC-1 do not affect SUV39H1 
activity. This indicates that downregulation of SUV39H1 is the initial event in the setting of 
obesity responsible for increased JMJD2C and SRC-1 recruitment to p66Shc promoter. Indeed, 
genetic disruption of SUV39H1 in lean control mice recapitulated obesity-induced epigenetic 
landscape on H3K9. Taken together, our results have unveiled a novel epigenetic mechanism 
underlying obesity-induced mitochondrial oxidative stress in vasculature (Figure 3).  
The analyses of recent clinical trials of antioxidants for cardiovascular disorder targeting 
ROS (ROS scavengers) have shown that they are ineffective and sometimes harmful 
therapeutic strategy 125. Accordingly, antioxidants partially scavenge cellular ROS without 
impacting mitochondrial redox signalling pathway 126. On contrary, modulation of SUV39H1 
expression may represent a novel therapeutic option to revert adverse H3K9 epigenetic 
modifications and oxidative stress in obese vasculature. 
 
Figure 3. Role of SUV39H1 in obesity-induced vascular oxidative stress. In normal weight, SUV39H1 
expression maintains H3K9 methylation levels preventing the binding of chromatin remodellers SRC-1 and 
JMJD2C to p66Shc promoter. In the presence of obesity, down-regulation of SUV39H1 facilitates recruitment of 
SRC-1/JMJD2C with reduced di-/trimethylation and acetylation of H3K9 on p66Shcpromoter. This chain of 
events fosters gene transcription of mitochondrial p66Shc, oxidative stress and endothelial dysfunction. 
H3K9me2, histone 3 lysine 9 dimethylation; H3K9me3, histone 3 lysine 9 trimethylation; H3K9ac, histone-3 
acetylation. 
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4.2. Hyperglycaemia-induced epigenetic changes drive persistant cardiac 
dysfunction via the adaptor p66Shc (STUDY II) 
Recent randomized clinical trials have failed to demonstrate major CV benefits with intensive 
glycaemic control in patients with diabetes. Hyperglycaemia remains associated with an 
increased risk of impaired left ventricular function and HF, even after targeting HbA1c levels 
<6.5% 127. In contrast with these findings, very recent data from the clinical trials showed that 
gliflozins, selective inhibitors of the sodium glucose cotransporter 2 (SGLT2i), reduce HF-
related outcomes in diabetic patients 128-130. Although these drugs are effective in reducing 
hyperglycaemic burden, SGLT2i-related benefits on HF are likely driven by other 
mechanisms including osmotic diuresis, effects on plasma volume, sodium retention with 
modulation of the cardio-renal axis and neurohumoral activation. Collectively, the analysis of 
clinical trials conducted so far suggests that hyperglycaemia may have long-lasting effects 
which persist even after normalization of blood glucose levels. Out of different 
hyperglycaemia-related signalling pathways, redox pathway plays a major role in the 
development of diabetic cardiomyopathy and HF 63. However, the molecular mechanisms 
regulating ROS generation in the diabetic heart are not yet fully understood. In the present 
study, we have investigated whether epigenetic changes may regulate derailed transcriptional 
programs in hyperglycaemia-induced mitochondrial oxidative stress and left ventricular 
dysfunction.  
Diabetes was induced in C57/B6 male mice by streptozotocin and followed for six weeks. 
After three weeks of diabetes, an additional group of mice received insulin treatment to 
achieve optimal glycaemic control (Figure 4A). After six weeks, mice were sacrificed and 
left ventricular specimens were collected for molecular studies. We found that mRNA and 
protein expression of adaptor p66Shc was significantly increased in diabetic heart compared to 
controls. Interestingly, glycaemic control did not revert such upregulation of p66Shc. p66Shc 
mitochondrial translocation and release of cytochrome c are important steps in ROS 
production and apoptosis 50. Therefore, we assessed p66Sh mitochondrial translocation and its 
interaction with cytochrome c in the different experimental groups. Mitochondrial 
translocation of p66Shc and its interaction with cytochrome c was significantly increased in 
diabetic heart despite of glycaemic control. Accordingly, mitochondrial O2- production was 
also increased in diabetic heart despite of glucose normalization (Figure 4B-E). Moreover, 
mitochondria isolated from diabetic heart showed persistent mitochondrial swelling, even 
after glucose normalization (see Figure 1; Paper II). 
  33 
 
Figure 4. Diabetes-induced p66Shc upregulation and mitochondrial oxidative stress are not reverted by 
glycaemic control. (A) Schematic showing study design. (B) Real time PCR and Western blot showing gene 
and protein expression of the adaptor p66Shc in control and diabetic mice, with or without intensive glycaemic 
control with insulin (n=5/group). (C) Western blot and relative quantification showing p66Shc mitochondrial 
translocation in left ventricular specimens from the different experimental groups (n=8/group). (D) 
Immunoprecipitation showing the interaction of p66Shc with cytochrome c. (E) ESR spectroscopy analysis and 
representative spectra of mitochondrial superoxide (O2−) anion in the 3 experimental groups (n=5-8/group). 
Given the ROS critical role in activation of inflammatory pathways 28, 29, we investigated 
myocardial inflammation in our setting. Interestingly, we found that NF-kB binding activity 
and its dependent genes VCAM-1, MCP-1 and IL-6 were significantly enhanced in diabetic 
heart despite of glucose restoration suggesting that ROS exerts myocardial inflammation (see 
Figure 1; Paper II).  
To investigate cardiac function, we performed standard and speckle-tracking 
echocardiography. Compared to control, diabetic mice showed an impaired left ventricular 
function assessed by fractional shortening (FS) and ejection fraction (EF). In addition, 
advanced measures of global and systolic cardiac performance represented by myocardial 
strain in longitudinal axis showed a clear impairment of LV function in diabetic mice as 
compared to controls. Of interest, glucose restoration did not revert such abnormalities (see 
Figure 2; Paper II). In order to investigate whether p66Shc drives myocardial dysfunction 
after glucose restoration, cardiac expression of p66Shc was blunted by specific RNA 
interference. Interestingly enough, we found that cardiac mitochondrial ROS generation was 
significantly reduced in p66Shc siRNA-treated mice as compared to mice treated with insulin 
alone . In line with these findings, mitochondrial swelling was persistent in diabetic mice that 
received insulin alone, while p66Shc silencing reduced this phenomenon. Accordingly, we also 
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showed that glucose normalization did not revert p66Shc-driven mitochondrial ROS 
generation, inflammatory pathways and left ventricular dysfunction. Indeed, silencing of 
p66Shc blunted mitochondrial oxidative stress, expression of VCAM-1, MCP-1 and IL-6 as 
compared to insulin alone. Of note, p66Shc knock-down during normoglycaemia was able to 
restore cardiac function. Thus, these findings indicate that persistent upregulation of p66Shc 
drive mitochondrial ROS despite of glucose restoration (see Figure 3; Paper II). To 
understand the epigenetic regulations of p66Shc, we found that DNA methylation was 
significantly reduced at active regions of p66Shc promoter in diabetic heart (see Figure 4; 
Paper II). Interestingly, glucose restoration was not able to revert such detrimental signature. 
To dissect the mechanism, we assessed the expression of methyltransferase DNMT3b that is 
a methyl-writing enzyme critical involved in DNA methylation 15, 83. We found that 
DNMT3b was downregulated in diabetic heart and such downregulation was not affected 
despite of glucose control. Moreover, interaction of DNMT3b to p66Shc promoter was 
reduced in diabetic heart despite of normoglycaemia restoration. DNA hypomethylation 
clustering with histone acetylation is a well-established posttranslational mechanism of active 
genes transcription 83. Hence, we next investigated the acetylation of histone 3 (H3) on p66Shc 
promoter. We found that H3 acetylation was significantly increased in diabetic heart despite 
of glucose control. Of note, the chromatin-modifying enzyme SIRT1 that is H3 deacetylase 
was persistently downregulated in the diabetic heart, regardless of glucose control(see Figure 
4; Paper II).. Accordingly, SIRT1-dependent deacetylation of p66Shc promoter was 
significantly reduced in diabetic heart and not improved by glucose normalization. To 
determine the impact of these chromatin modifiers on p66Shc cardiac transcription, we 
reprogrammed SIRT1 and DNMT3b in human cardiomyocytes. In line with our in vivo 
findings, we found that SIRT1 and DNMT3b were persistently downregulated in glucose-
treated cardiomyocytes despite of glucose normalization. Interestingly, DNMT3b and SIRT1 
blunted suppressed p66Shc upregulation and ROS production (see Figure 4; Paper II).  
The pivotal role of miRNAs in posttranscriptional regulation has recently emerged as a key 
underlying mechanisms with direct impact on cardiovascular diseases 131. For that reason, we 
investigated whether miRNAs modulate DNMT3b and SIRT1 expression, hence affecting 
chromatin architecture and cardiac p66Shc transcription. By using in silico prediction analysis, 
we found that DNMT3b and SIRT1 were targets of miR-218 and miR-34a, and expression of 
these miRNAs was markedly increased in diabetic heart despite of glucose normalization (see 
Figure 4; Paper II).. Interestingly enough, silencing of miR-218 and miR-34a blunted p66Shc 
transcription and oxidative stress as compare to restoration of normoglycaemia alone. Taken 
together, miR-218 and miR-34a target chromatin modifying enzymes DNMT3b and SIRT1 
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leading to persistent p66Shc upregulation despite of glucose normalization (see Figure 4; 
Paper II).  
Previous studies have shown that poor glycaemic control is associated with an increased risk 
of HF. In contrast to this observation, recent clinical trials have unexpectedly reported that 
intensive glycaemic treatment fails to reduce HF-related outcomes in patients with diabetes. 
Combined analysis of clinical trials suggests that hyperglycaemia may have long-lasting 
effects that may persist even after blood glucose normalization 132. These findings support the 
notion that hyperglycaemic environment may be remembered in diabetic heart, and this might 
lead to persistent cardiac damage and dysfunction despite of glucose normalization. 
Mitochondrial redox signalling pathway may probably be involved in this effect. However,  
the underlying molecular mechanism remains to be unveiled. Mitochondrial overproduction 
of ROS alters cardiomyocytes function leading to cardiac damage. In the present study, we 
have postulated that dynamic epigenetic changes may contribute to affect transcription 
programs implicated in hyperglycaemia-induced oxidative stress and myocardial damage. 
Epigenetic changes are heritable changes in gene expression without alterations in the 
underlying DNA sequence 112. These non-genetic changes are strictly attributed to three 
major epigenetic signatures: DNA methylation, histone modifications, and non-coding 
RNAs. In addition to other regulatory transcriptional mechanisms, epigenetic modifications 
modulate gene activity in development and differentiation, or in response to environmental 
stimuli 111. Here in this study we show that epigenetic modifications, such as DNA 
hypomethylation and H3 acetylation, drive p66Shc transcription, a key protein involved in 
mitochondrial ROS production and apoptosis 66.  Of interest, adverse epigenetic signatures on 
p66Shc promoter were not erased by glucose normalization, suggestion that these epigenetic 
modifications are pivotal in maintenance of myocardial oxidative stress during subsequent 
normoglycaemia. Further mechanistic experiments revealed that persistent deregulation of 
chromatin modifiers DNMT3b and SIRT1 underlined p66Shc promoter remodelling. Indeed, 
DNMT3b and SIRT1 overexpression in cardiomyocyte blunted p66Shc persistent upregulation 
by regulating chromatin accessibility. Furthermore, we demonstrated that miR-218 and miR-
34a were upstream regulators of DNMT3b and SIRT1. MiRNAs are a recently discovered 
class of noncoding RNAs that have emerged as important regulators of gene expression 133.  
Albeit, previous studies have demonstrated that miRNAs are aberrantly expressed in 
cardiovascular pathologies 131, however their role in the modulation of chromatin modifying 
enzymes remains unknown. Our results unmask novel epigenetic mechanisms linking 
miRNAs with modifications of DNA-histone complexes and persistent upregulation of 
adaptor gene p66Shc. We show that miR-218 upregulation in diabetic heart epigenetically 
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contributes to persistent p66Shc-related mitochondrial oxidative stress via regulation of the 
methyltransferase DNMT3b. Although, the role of miR-218 have been investigated in heart 
development 134, 135 and vascular remodelling 136, its role in myocardial oxidative stress and 
cardiac dysfunction remains unclear. Our results indicate that diabetes-induced upregulation 
of miR-218 promotes adverse epigenetic remodelling of p66Shc promoter in the heart. Indeed, 
upregulation of miR-218 causes downregulation of DNMT3b leading to hypomethylation of 
CpG dinucleotides, and increased transcription of p66Shc. In line with these findings, we also 
found that miR-34a indirectly modulates H3 acetylation via epigenetic repression of the 
deacetylase SIRT1. MiR-34a inhibition blunted persistent p66Shc upregulation and oxidative 
stress during subsequent normoglycaemia, suggesting that miR-34a is an important 
epigenetic regulator of mitochondrial ROS generation. Similarly, it has been shown recently 
that epigenetic silencing of miR-34a protects against maladaptive cardiac remodelling and 
myocardial damage following acute myocardial infarction 137. In summary, our results 
suggest that targeting miR-218 and miR34a may represent a potential therapeutic strategy 
against mitochondrial oxidative stress in the diabetic heart, regardless of intensive glycaemic 
control (Figure 5). 
 
 
   
 
 
 
 
 
Figure 5. Schematic summarizing miR-218 and miR-34a orchestrate p66shc transcription by targeting 
DNMT3b, DNA Methyltransferase 3 Beta and SIRT1, Sirutin 1. 
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4.3. Protective role of AP-1 transcription factor JunD in the diabetic heart 
p66Shc (STUDY III) 
Understanding the precise molecular mechanism that lead to oxidative stress in the diabetic 
heart is a major challenge to reduce cardiovascular disease burden over the next decades. 
Although ROS-dependent pathways have been intensively studied in hyperglycaemic 
conditions, the link between hyperglycaemia and free radical generation remain to be 
elucidated. The Activated Protein-1 (AP) transcription factor JunD is emerging as an 
important modulator of oxidative stress 78. AP-1 is a family of dimeric complexes made by 
different members of three families of DNA-binding proteins: Jun, Fos, and ATF/CREB 78, 
138-140. These members assemble to form AP- 1 transcription factor and exert functional 
effects that are strongly influenced by their specific components as well as their cellular 
environment 78, 138. In the present study we have investigated the role of JunD in diabetes-
induced ROS-driven myocardial damage.  
To investigate the role of JunD in the diabetic heart, diabetes was induced in WT and cardiac 
specific JunD transgenic mice (α-MHC-JunDtg ) of JunD by streptozotocin (Figure 6 A). 
After four weeks of diabetes, cardiac function was assessed by standard and speckle-tracking 
echocardiography in all four experimental groups. WT diabetic mice showed an impaired left 
ventricular function as compared to controls, as assessed by reduced FS and EF (see Figure 
3; Paper III). Accordingly, myocardial strain in longitudinal axis revealed a clear 
impairment of LV function in WT diabetic mice as compared to controls. Of interest, such 
abnormalities were not observed in α-MHC-JunDtg diabetic mice (see Figure 3; Paper III). 
Then, mice were euthanized and hearts were collected for molecular analyses. We found that 
gene and protein expression of JunD were significantly reduced in the heart of diabetic mice 
as compared to controls (Figure 6 B-C). This downregulation of JunD in WT mice was 
associated with increased myocardial O2− generation as assessed by ESR spectroscopy. In 
contrast, MHC-JunDtg diabetic mice were protective against elevated O2− generation (see 
Figure 4; Paper III).  
 
 
 
 
 38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  (A) Schematic representation of experimental groups. (B) Bar graphs showing downregulation of 
JunD mRNA and (C) protein expression in in wild-type (WT) diabetic mice as compared to controls. Results are 
presented as mean ± SEM; n=4-6 per group. 
It is well established that diabetes alters the balance between pro- and anti-oxidants enzymes 
resulting in oxidative stress. Since JunD down-regulation was associated with an increased 
O2- generation in WT diabetic heart, we investigated the effect of JunD on ROS-generating 
and ROS-scavenging enzymes in diabetic heart in the presence or absence of cardiac 
overexpression of JunD. We found that gene and protein expression of superoxide dismutase 
1 (SOD1) and aldehyde dehydrogenase 2 (ALDH2) were decreased in the heart of WT 
diabetic mice. While, NADPH oxidase subunits NOX2 and NOX4 were significantly 
upregulated as compared to WT controls. Interestingly enough, such detrimental changes 
were not found in the heart of MHC-JunDtg diabetic mice suggesting that JunD is required for 
redox balance under diabetic conditions ((see Figure 4; Paper III)). In agreement with JunD 
downregulation, its binding on the promoter of anti-oxidant (SOD1 and ALDH2) and pro-
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oxidant (NOX2 and NOX4) genes was significantly reduced in WT diabetic mice (see Figure 
5; Paper III).  
Given that ROS is a pivotal activator of inflammatory pathways, we investigated nuclear 
factor-kappa B (NF-κB)-dependent transcriptional programs in our setting. We found that 
NF-κB activity as well as NF-κB-dependent inflammatory genes MCP-1, IL-6, TNFα were 
significantly enhanced in the heart of WT diabetic mice as compared to controls (Figure 4). 
In line with these findings, gene expression of IkB, the inhibitory subunit of NF-κB was 
reduced. Of interest, MHC-JunDtg diabetic mice were protected against the derangement of 
these inflammatory pathways (see Figure 6; Paper III).  
Since it is well known that DNA methylation and histone modifications modulate gene 
expression, DNA methylation and posttranslational modifications of histone H3 at JunD 
promoter were investigated. We found that DNA methylation level of CpG islands in the 
promoter region of JunD was gene was significantly elevated in the heart of WT mice with 
diabetes as compared to controls. Accordingly, the active marks histone 3 lysine 4 
trimethylation (H3K4me3) and histone 3 lysine 4 monomethylation (H3K4me1) were 
significantly reduced in WT diabetic heart as compared to controls. In contrast, we found that 
repressive histone 3 lysine 9 trimethylation (H3K9me3) was increased in the heart of WT 
diabetic mice as compared to controls (see Figure 7; Paper III). As a translational approach, 
left ventricular specimens were collected from patients with diabetes and heart failure and 
age-matched controls. Interestingly, JunD gene and protein levels were significantly reduced 
in patients compared to controls.  
 
 
 
 
 
 
 
Figure 7. JunD expression in human heart. (A) mRNA and (B) protein expression of JunD in controls and in 
patients with diabetes and heart failure.  
 40 
Ap-1 transcription factor JunD protects against oxidative stress and modulates different genes 
implicated in growth, proliferation and survival 140-142. Previous studies have shown that ROS 
generation was increased in JunD-/- immortalized cells 75. We have recently demonstrated that 
JunD deletion is associated with vascular oxidative stress and premature endothelial 
dysfunction in aging 78. Of note, JunD-/- mice display reduced life span 76, 77, 143. The 
observation that JunD gene and protein expression were reduced in the heart of diabetic WT 
mice prompted us to investigate the link between JunD downregulation and derailed 
oxidative/inflammatory myocardial pathways and its contribution to myocardial dysfunction. 
ROS accumulation alters myocytes function by triggering the cardiac inflammatory pathways 
and fibrosis 62, 63. Here we have demonstrated that ROS accumulation in the myocardium was 
associated with impaired balance between ROS-scavenging and -producing enzymes. Indeed, 
SOD1 and ALDH2 were significantly reduced in WT diabetic mice suggesting that JunD is 
required for their transcription. It has been recently reported that ALDH2 protects against 
diabetes-induced myocardial dysfunction 144. Accordingly, ALDH2 also protects against 
cardiac ischemia/reperfusion injury 145-147. Here we showed that JunD downregulation in 
diabetic heart impairs ALDH2 expression, which may contribute to abnormal myocardial 
redox haemostasis. Our results are in line with the established role of JunD in transcriptional 
activation of genes involved in detoxification 148. Of note, anti-oxidant response elements 
have been reported in the promoter regions of ROS-scavenging enzymes 149. On the other 
side, we found that NOX2 and NOX4 were upregulated in the heart of WT diabetic mice. In 
agreement with ROS-induced NF-κB-dependent inflammatory pathway 150, inhibitory 
subunit of NF-κB was reduced, whereas MCP-1, IL-6, and TNFα genes were enhanced in the 
heart of WT diabetic mice. On contrary, α-MHC-JunDtg mice were protected against 
myocardial oxidative stress, inflammation and left ventricular dysfunction suggesting that 
modulation of JunD expression plays a key role in ROS-driven left ventricular dysfunction. 
In line with our findings, it has been reported that adenoviral overexpression of wild-type 
JunD protects against phenylephrine-mediated cardiomyocyte hypertrophy 80. Similarly, 
another study has shown that JunD also protect against myocardial apoptosis and 
hypertrophy-induced by pressure overload 81.  
To dissect the molecular mechanism of JunD downregulation in diabetes, we investigated the 
modulation of JunD at the transcriptional level. Our analysis of JunD promoter showed a 
significant hypermethylation of CpG island in the heart WT diabetic mice compared to 
controls. Indeed, DNA methylation is a repressor of gene transcription in mammals 83.  In 
addition, we also found a deranged pattern of histone marks with reduced active marks such 
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as H3K4me3 and H3K4me1 and an increased level of the repressive mark H3K9me3. 
Histone posttranslational modifications, such as acetylation and methylation regulate gene 
expression by affecting their chromatin architecture 83. Taken together, our results unveiled 
the epigenetic mechanisms responsible for JunD downregulation in diabetes, which could 
become novel therapeutic targets. Of note, JunD expression was significantly downregulated 
at both mRNA and protein level in heart tissues obtained from human diabetic patients. These 
findings indicate that downregulation of JunD may contribute to ROS-driven myocardial 
damage also in humans providing a translational perspective to our findings (Figure 8).  
 
Figure 8 Schematic representation of JunD role in hyperglycemia-induced myocardial dysfunction. Under 
control conditions JunD protects against cardiac oxidative stress and inflammation by modulating the expression 
of genes involved in anti-oxidant defence system. However, in the setting of diabetes downregulation of JunD, 
mediated via DNA methylation and post-translational modifications of histones on JunD promoter, contributes to 
myocardial dysfunction by triggering overexpression of pro-oxidant and pro-inflammatory genes. 
 
4.4. Inhibition of histone methyltransferase EZH2 blunts glucose-induce 
oxidative stress and inflammation in human aortic endothelial cells 
(STUDY IV)  
Oxidative stress and inflammation are tightly interlinked processes involved in the 
pathogenesis of diabetes-associated endothelial dysfunction 148.  Previous studies have been 
reported that elevated ROS levels and inflammation are responsible for endothelial 
dysfunction in diabetes 26, 115. However, little is known about the molecular mechanisms 
underpinning increased ROS production and inflammation in diabetes.  Enhancer of zeste 
homolog 2 (EZH2) is a histone methyltransferase that specifically catalyzes trimethylation of 
histone H3 at lysine residue 27 (H3K27me3) and, eventually, transcriptional repression 149. 
Indeed, EZH2-depended chromatin remodeling fosters accumulation of free radicals and 
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inflammation 100, 108.  Pharmacological targeting of EZh2 in different cancer types has been 
found to be effective, however it remains unknown whether targeting EZH2 may reduce 
hyperglycemia-induced oxidative and inflammatory transcriptional programs. In the present 
study, we have investigated whether pharmacological inhibition of EZH2 by GSK126 
attenuates hyperglycemia-induced oxidative stress and inflammation in human aortic 
endothelial cells (HAECs).  
To investigate the effects of hyperglycemia on EZH2 activity, HAECs were exposed to high 
(HG) and normal glucose (NG) levels for 20 hours. We found a significant increase of 
histone H3K27me3 modification in HAECs exposed to a high glucose environment (Figure 
9A). Indeed, EZH2 inhibition by GSK126 blunted EZH2 enzymatic activity as assessed by 
H3K27me3 protein analysis (Figure 9A). MTT is a calorimetric assay used for cell metabolic 
activity. MTT assay was performed to measure the cytotoxicity of the drug at different 
concentrations. As a result, no significant difference in HAEC viability was observed up to 5 
µM concentration of GSK126. This 5 µM concentration of GSK126 was then used in 
subsequent experiments (Figure 9B).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. H3K27me3 expression and cell viability in the absence and the presence of GSK12 (A) EZH2 
activity measured as H3K27me3 expression by western blot analysis. (B) Cell viability assessed by MTT assay. 
Results are presented as means ± SEM; n=3. Bonferroni-adjusted p values are shown for multiple comparisons. 
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HAECs exposed to HG showed a significant increase in endothelial O2− generation as 
compared to NG (see Figure 2; Paper IV). Interestingly enough, EZH2 inhibition by 
GSK126 abolished O2− generation in HAECs exposed to HG. Gene and protein expression of 
dismutase 1 (SOD1) and superoxide dismutase 2 (SOD2), major ROS-scavenging enzymes 
were significantly reduced in HAECs exposed to high glucose. By contrast, GSK126 
treatment prevented glucose-induced down-regulation of ROS-scavengers. EZH2-mediated 
H3K27me3 was significantly increased on the promoter of SOD1 and SOD2 genes in 
HAECs exposed to high glucose (see Figure 2; Paper IV). Of interest, GSK126 blunted HG-
induced trimethylation of H3K27 on promoter of SOD1 and SOD2 genes (see Figure 2; 
Paper IV). Accordingly, gene and protein expression of NOX4, a well-known source of 
ROS, were increased in HAECs exposed to HG. This increased expression of NOX4 was 
blunted by GSK126 treatment in HAECs exposed to HG (see Figure 3; Paper IV).  
Mechanistic studies have previously shown that AP-1 transcription factor JunD protects cells 
against oxidative stress by modulating NOX4 expression75. Therefore, we investigated 
binding of JunD on NOX4 promoter. Interestingly, we found that binding of JunD on NOX4 
promoter was significantly reduced in HAECs exposed to HG. In contrast, GSK126 was able 
to restore the binding of JunD to NOX4 promoter. Furthermore, we also found that glucose-
induced down-regulation of JunD was inhibited by GSK126. Indeed, high glucose-induced 
down-regulation of JunD was associated with increased H3K27me3 on JunD promoter. 
Interestingly, H3K27me3 was markedly reduced by GSK126 treatment (see Figure 3; Paper 
IV). Due to the effect of ROS on the activation of inflammatory pathways, NF-κB p65 
binding activity and expression of MCP-1 and IL-6 genes were assessed and found to be 
enhanced in HAECs exposed to HG as compared to control cells 150. Of interest, GSK126 
abolished these detrimental inflammatory programs (see Figure 4; Paper IV). In line with 
these findings, we also found that the expression of SOD1, SOD2 and JunD genes was 
significantly reduced in human aortic endothelial cells isolated from patients with diabetes 
(D-HAECs) as compared to control HAECs). In contrast, we found an up-regulation of 
NOX4, MCP-1 and IL-6 gene expression in D-HAECs, which could be   reprogrammed by 
GSK126 treatment (see Figure 5; Paper IV). 
Previous studies have demonstrated that oxidative stress and inflammation play a key role in 
the progression of endothelial dysfunction in diabetes 148, 151-153. EZH2 is a methyltransferase 
belongs to SET1 family of methyltransferase, and is well known for its transcriptional 
repression via H3K27me3 histone modification 109.  The importance of EZH2 in maintenance 
of cellular haemostasis is outlined by the fact that its deregulation causes disease phonotypes, 
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such as cancer, neurodegenerative disease, cardiac and vascular dysfunction 100, 109, 154, 155. A 
recent study showed an increased EZH2 expression and activity in endothelial cells exposed 
to high glucose 156. Here we demonstrate that increased endothelial ROS generation was 
associated with derailed gene expression involved in redox signalling pathway. Our ChIP 
analysis revealed that the interaction of JunD and NOX4 promoter was significantly reduced 
in HAECs exposed to high glucose suggesting that HG deregulate NOX4 expression via 
JunD. NOX4 has been found a major source of ROS generation, and it contributes to 
endothelial dysfunction in diabetes 157. Indeed, targeting NOX4 protects against ROS-driven 
endothelial dysfunction 158.  We found that down-regulation of JunD in HAECs exposed to 
high glucose is dependent on methyl-writing activity of EZH2. Targeting EZH2 by GSK126 
in HAECs exposed to HG blunted EZH2 dependent signatures on JunD promoter and 
restored JunD expression. JunD was showed to protect against oxidative stress by modulating 
genes involved in redox signalling pathway 78. Accordingly, JunD-/- immortalized cells 
showed increased ROS generation suggesting that JunD is crucial in maintaining the redox 
homeostasis 75. ROS-scavengers such as SOD1 and SOD2 are important mediators of the 
redox balance. Our results have demonstrated that hyperglycaemia-induced endothelial ROS 
generation was associated with significantly down-regulation with SOD1 and SOD2. In line 
with our findings, it has been recently reported that SODs play a crucial role in oxidative 
inhibition of nitric oxide (NO), thus preventing peroxynitrite and preserving endothelial 
function 159. Furthermore, we also demonstrate that active transcription of SODs depends on 
methyltransferase activity of EZH2. GSK126 preserved the endothelial redox balance by 
inhibiting glucose-induced down-regulation of SODs. We also provide strong evidence that 
EZH2 drives endothelial inflammation in HAECs in the setting of diabetes. Although, it has 
been shown recently that EZH2 promotes NF-kB signalling in liver failure 160, no previous 
studies have investigated whether EZH2 mediates inflammation in HAECs. In our study 
EZH2 induce NF-kB nuclear translocation and up-regulation of adhesion molecules in 
HAECs exposed to HG and also in D-HAECs. However, pharmacological inhibition of 
EZH2 by GSK126 suppressed NF-κB p65 activity and expression of IL-6 and MCP-1. These 
results deserve attention since NF-κB p65 activation has been recently reported in 
endothelium of patients with type 2 diabetes.46 These results uncover adverse epigenetic 
signatures underlying endothelial dysfunction in diabetes. Targeting EZH2 may attenuate 
oxidative and inflammatory transcriptional programmes and thus prevent vascular disease in 
this setting (Figure 10) 
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Figure 10. Schematic representation of the role of EZH2 in glucose-induced redox imbalance and 
inflammation. (A) High glucose–induced, EZH2-mediated H3K27me3 leads to oxidative stress and 
inflammation. (B) GSK126, an EZH2 specific inhibitor preserves redox balance and, hence, blunts the activation 
of inflammatory signalling. NADPH oxidase subunit NOX4 is regulated via recruitment of JunD on its promoter 
whereas SOD-1 and SOD-2 expression is maintained by inhibiting H3K27me3 writing activity of EZH2.  
 
5 CONCLUDING REMARKS 
 
The worldwide rising prevalence of diabetes and obesity is closely linked to cardiovascular 
morbidity and mortality. However, the current understanding of the signaling pathways 
triggering cardiovascular damage is still limited and, most of all, novel mechanism-based 
therapeutic approaches are in high demand. Oxidative stress and inflammation are well-
established pathophysiological players. The epigenetic changes of DNA/histone complexes 
are emerging as critical regulators of transcriptional programs of oxidant and pro-
inflammatory genes. Given this background the herewith thesis was designed to study the 
epigenetic mechanisms which may contribute to the onset of abnormal cardiovascular 
phenotypes. State-of-the-art techniques for the assessment of DNA methylation, histone 
modifications and non-coding RNAs (microRNAs) have been used both in obesity and 
diabetes experimental models as well as in human subjects to determine the role of such 
epigenetic signatures in triggering redox and inflammatory-mediated cardiovascular injury.  
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Specifically, we were able to identify a dynamic interplay among histone 3 lysine 9 (H3K9)-
modifying enzymes SUV39H1, JMJD2C and SRC-1 orchestrating the transcriptional 
regulation of the adaptor p66Shc, with subsequent mitochondrial ROS generation and vascular 
dysfunction. Moreover, we demonstrated that p66Shc transcription, ROS generation and left 
ventricular dysfunction in the heart of diabetic mice treated with high glucose is driven by a 
complex epigenetic mechanism linking miR-218/miR34a and chromatin editing enzymes 
DNMT3b/SIRT1. Interestingly, these promoter-related marks were not erased by intensive 
glycemic control, suggesting that epigenetic mechanisms are crucial for the maintenance of 
myocardial oxidative stress during subsequent normoglycaemia. These findings unveil novel 
epigenetic networks linking miRNAs with modifications of DNA/histone complexes. 
Targeting miR-218 and miR34a may thus represent a promising approach to blunt ROS 
generation in the diabetic heart, regardless of glycaemic control. 
Recent evidence support the notion that the activator protein-1 (AP-1) transcription factor 
JunD is a key molecule implicated in ROS-driven cardiovascular aging. Here, we 
demonstrate that a reduced expression of JunD contributes to derangement of ROS 
homeostasis, inflammation and cardiac damage. Hyperglycemia-induced JunD 
downregulation is epigenetically regulated. Interestingly enough, diabetic mice with cardiac-
specific overexpression of JunD were protected against ROS-driven damage. This work 
provides important molecular insights on the role of transcription factor JunD in diabetes-
induced myocardial dysfunction and might open novel therapeutic perspectives in this setting. 
It is indeed emerging that epigenetic changes are amenable to pharmacological intervention. 
To this aim we investigated the effect of selective inhibition of histone methyltransferase 
EZH2 on glucose-induced impairment of endothelial redox and inflammatory pathways. 
Interestingly enough, selective inhibitor GSK126 restored the transcription of anti-
oxidant/anti-inflammatory genes, which was blunted by EZH2-mediated repressive 
H3K27me3 mark.  
 
6 FUTURE PERSPECTIVES 
 
All together our findings unravel a complex scenario linking enzymes implicated in 
chromatin remodelling, ROS generation and vascular inflammation. Undoubtedly they shed 
some light on epigenetic networks and open perspectives for their pharmacological targeting 
to correct deregulated gene expression as a strategy to alleviate the cardiovascular burden of 
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obesity and diabetes. However, it is important to consider that we are just starting to become 
aware of the role and complexity of epigenetic mechanisms in health and disease. 
Environmental factors potently influence epigenetic variations and altered gene expression 
over the life time. The causal nexus between epigenetic events and abnormal cardiovascular 
phenotype requires careful assessment. Larger studies combining epigenome, transcriptome 
and clinical data are needed to further elucidate the interaction between epigenetics and 
cardiovascular disease and eventually to develop personalized therapeutic strategies. 
 
7 LIMITATIONS 
 
Although in study I we have successfully translated our experimental findings to the human 
setting, we could not fully prove a causal relation between p66Shc and endothelial dysfunction 
in obese patients. In this regard, pharmacological modulation of p66Shc would have been the 
best approach but, p66Shc inhibitors are not yet available. An important aspect which deserves 
further investigation is whether epigenetic regulation of p66Shc may counteract the 
atherosclerotic phenotype in this setting. Finally, ChIP experiments were performed in mouse 
and human vascular homogenates containing a variety of cell types. Therefore, we cannot 
fully rule out that epigenetic regulation of smooth muscle cells, macrophages, or other 
vascular cells may participate to obesity-related vascular phenotype. As shown in study II 
modulation of miRNA expression represents a highly promising approach. However, it may 
leads to undesirable effects due to hybridization-associated off-target effects. This lack of 
target specificity highlights the need for caution in the development of therapeutics targeting 
a single miRNA. Although further work is warranted to address the potential of miRNA-
targeting therapeutics in this setting, our study has the strength to unveil novel epigenetic 
connections and their potential role in diabetic cardiomyopathy. Another limitation of the 
present study is represented by the duration of glycemic control period (3 weeks), which may 
not be sufficient to exert a significant impact in restoring defects of cardiac performance 
initiated by hyperglycemia. However, an increasing body of evidence suggests that the bad 
legacy effect of hyperglycaemia is long-lasting and detrimental. We recently showed that 
oxidative stress and vascular dysfunction persist even after 6 months of glycemic control in 
patients with type 2 diabetes. Other recent reports in vitro and in vivo support this concept, by 
showing that short exposure to hyperglycemia induces long lasting effects on the endothelium 
and the myocardium. It is noteworthy that in the experimental setting of study III we have 
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used a STZ model of T1D to demonstrate the protective role of JunD in hyperglycemia-
induced, ROS-mediated myocardial dysfunction. However, the translational perspective of 
our experimental findings was obtained only in a very limited number of patients with T2D 
and heart failure (n=5) as well as in age-and gender-matched controls (n=6) for which we had 
available specimens of the left ventricle. The IV study designed to investigate whether EZH2 
may represent a novel therapeutic target in hyperglycemia-induced oxidative stress and 
inflammation was performed only in vitro in HAECs exposed to high glucose and in 
endothelial cells isolated from patients with diabetes (D-HAECs). In order to conclude that 
such reprogramming of adverse epigenetic signatures determines the observed attenuation of 
oxidative and inflammatory transcriptional programmes these results have to be confirmed in 
vivo.  
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